The documentary series about how molecules became medicines aired a new episode last month focusing on BCL-2, which targets blood cancer.
The premiere took place at the end of January, and the debut of another one is planned for the end of 2023.
In the latest episode, Andy Sauers, AbbVie oncology researcher, talks about the years that, starting with the first chemical analysis, through failure, round-the-clock work, and innovative thinking, led to the start of venetoclax clinical trials.
